Platform deals are rising in pharma and healthcare, says Rothschild MD
In short
Platform deals are rising in pharma and healthcare, Rothschild & Co. Managing Director Subhakanta Bal said. The report says a platform model starts with one strong company and then adds smaller companies or brands to grow.
This could matter for deal-making in those sectors, but the report does not name any specific transactions. It is still unknown which companies are involved or how large the deals are.
What the reporting says
Platform deals are on the rise in pharma and healthcare, Rothschild & Co. Managing Director Subhakanta Bal said in a publisher summary. The report says a platform model means buying a strong initial company and then adding smaller companies or brands to build scale and capabilities. It does not name any specific deals, buyers, targets, or timing.
Why it matters
Platform deals are said to be rising in pharma and healthcare, according to Rothschild & Co. Managing Director Subhakanta Bal. The reporting explains the model as buying a strong platform company and then adding smaller companies or brands to expand scale and capabilities. It does not name any deals, parties, or valuations, so the market impact remains unclear.